Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Personalis ( (PSNL) ) just unveiled an announcement.
On May 12, 2026, Personalis received expanded Medicare coverage from the Centers for Medicare & Medicaid Services Molecular Diagnostics Program for its NeXT Personal test. The coverage now includes immunotherapy monitoring for patients with late-stage solid tumors, potentially broadening patient access and reinforcing the test’s role in guiding advanced cancer treatment decisions.
This expansion is expected to enhance Personalis’ positioning in the precision oncology testing market by validating the clinical utility of NeXT Personal in real-world care settings. It may also support increased adoption of the test by healthcare providers treating late-stage cancer patients who rely on immunotherapy-based regimens.
The most recent analyst rating on (PSNL) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on Personalis stock, see the PSNL Stock Forecast page.
Spark’s Take on PSNL Stock
According to Spark, TipRanks’ AI Analyst, PSNL is a Neutral.
The score is held down primarily by weak financial performance—shrinking TTM revenue, very low margins, large losses, and continued cash burn—despite a relatively conservative balance sheet. Technicals add pressure with the stock trading below key moving averages and negative MACD. The earnings call provides some offset via reaffirmed guidance, accelerating clinical volume, and reimbursement progress, but near-term margin and cash burn risks remain significant.
To see Spark’s full report on PSNL stock, click here.
More about Personalis
Personalis operates in the molecular diagnostics and precision oncology industry, providing advanced genomic testing solutions. Its ultrasensitive NeXT Personal test is designed for highly precise cancer detection and monitoring, with a focus on supporting treatment decisions for patients with solid tumors and other cancer types.
Average Trading Volume: 1,739,985
Technical Sentiment Signal: Sell
Current Market Cap: $632.5M
For an in-depth examination of PSNL stock, go to TipRanks’ Overview page.